# PML Tools and StratifyJCV
Keywords: PML, StratifyJCV, TYSABRI, multiple sclerosis, JCV antibody, brain infection, risk management, healthcare professionals

> This page provides information for healthcare professionals about PML risk management tools, including StratifyJCV, to support decision-making for patients considering or on TYSABRI treatment.

## Details
- [Making a well-rounded decision](#): Overview of TYSABRI's use in treating RRMS, its association with PML, and the role of StratifyJCV in assessing JCV antibody levels.
- [Biogen’s continuing commitment to helping HCPs manage PML risk](#): Highlights Biogen's resources for healthcare professionals to assess and mitigate PML risks.
- [PML risk estimates algorithm](#): Explanation of the algorithm incorporating key risk factors such as JCV antibodies, prior immunosuppressant use, and TYSABRI treatment duration.
- [Managing PML risk](#): Discusses early detection, patient monitoring, and guidelines to improve outcomes for patients at risk of PML.
- [Incidence of TYSABRI-associated PML](#): Provides data on global PML incidence among TYSABRI-treated patients and key milestones in risk stratification.
- [The 'guard dog' analogy for MS and TYSABRI's MoA](#): Uses a metaphor to explain TYSABRI's mechanism of action and its effects on multiple sclerosis.
- [StratifyJCV™ - Help](#): Describes the StratifyJCV service funded by Biogen for patients considering or on TYSABRI treatment.